Astec LifeSciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astec LifeSciences Limited has announced its audited financial results for Q4 and FY2026. The statutory auditors, B S R & Co. LLP, have issued unmodified (clean) opinions on both standalone and consolidated financial results, confirming they present a true and fair view. The results show a net loss for the year ended March 31, 2026 on both standalone and consolidated basis. The Board has fixed the 32nd AGM for July 31, 2026 with book closure from July 26-30, 2026. The company is seeking shareholder approval via postal ballot for appointment of four directors and approval for material related party transactions for FY2026-27.
The net loss for FY2026 is a concern for shareholders, though the clean audit opinion provides assurance on financial reporting accuracy. The upcoming related party transaction approvals warrant shareholder attention ahead of the postal ballot.